Agenda
Applications for consideration at this meeting
- 1196.2 Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (resubmission)
- 1342.5 Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (resubmission)
- 1435.1 Processing and Cryopreservation of Ovarian Tissue
- 1510.1 Emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with Haemophilia A
- 1515 Endoscopic placement and removal of an intra-gastric balloon (IGB) for the management of overweight and obesity in a high-risk patient
- 1519.1 Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 1525 Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer
- 1562 Streamlining Medicare Benefits Schedule Items for Positron Emission Tomography (PET) Project
- 1579 Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate to severe Haemophilia A (congenital Factor VIII deficiency) WITHOUT Factor VIII inhibitors
- 1589 Prognostic value of the number of copies of the survival of motor neurone 2 (SMN2) gene for the severity of spinal muscular atrophy to determine eligibility for nusinersen in pre-symptomatic patients (Co-dependent)
Related information
Committee: